Table 1. Characteristics of the studies included in the meta-analysis.
| First Author | Year | Country | NO. of patients | Age, median (range) | IHC evaluation method | Antibody | Cut-off | PD-L1 positive (%) | Follow up Median (range) (M) | Quality assessment (score) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Source | Type | Clone | ||||||||||
| Li | 2016 | China | 501 | 53 (29-83) | H-score | Abcam, UK | Rabbit | PAB | ab58810 | ≥100 scores | 231/501 (46.1) | 64 (1-80) | 7 |
| Baptista | 2016 | Brazil | 192 | NA | H-score | Abcam, UK | Rabbit | PAB | NA | ≥2 | 107/189 (56.6) | 86 | 6 |
| Muenst | 2014 | Switzerland | 650 | 64 (27-101) | H-score | Abcam, UK | Rabbit | PAB | M1H1 | ≥100 scores | 152/650 (23.4) | 65 (1-174) | 6 |
| Park | 2016 | Korea | 333 | 47 (28-78) | H-score | Abcam, UK | Rabbit | PAB | NA | ≥3 | 163/316 (51.6) | 118 (5-154) | 6 |
| Qin | 2015 | China | 870 | 47 (21-84) | Percentage | CST, USA | Rabbit | MAB | NA | ≥5% | 189/870 (21.7) | 98 (17-265) | 7 |